Abstract 15863: Prevalence, Trends and Impact of Cannabis Use on Hospitalizations With Prior Myocardial Infarction and Revascularization

Abstract

Background: With the rise of cannabis use in the USA, we aim to assess its prevalence and impact on admissions with prior myocardial infarction and revascularization [percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG)]. Methods: We queried the National Inpatient Sample (2007-2014) to identify admissions with prior MI/PCI/CABG for the prevalence, trends and impact of cannabis use disorder. Results: Patients cohort with prior MI and revascularization with cannabis use consisted of younger (median age years 53 (46-59) vs 72 (63-81), African American (34.3% vs. 10.0%) male (76.5% vs. 61.5%) patients v/s non cannabis users (p<0.001). Co-morbid conditions such as hypertension (71.7% vs. 74.8%), diabetes, uncomplicated (23.6% vs. 32.9%), dyslipidemia (51.3% vs. 57.8%) (p< 0.001) were significantly lower in cannabis users. There were increasing trends of cannabis use from 0.2 to 0.7% over the study period with a higher rate of AMI (7.2% vs 4.5%), PCI (6.2% vs 5.5%) and CABG (1.9% vs 1.5%) in cannabis users as shown in Fig 1a and 1b . All-cause mortality (0.8% vs 2.5%), hospital charges (21556 vs 24872) were low among cannabis users. Subsequent AMI in cannabis users was 67% v/s 41% in non-cannabis users. Conclusion: There are alarmingly rising trends in cannabis use in patients with prior MI/PCI/CABG from 2017-2014. Even with younger and overall lower comorbidity burden in cannabis users, the frequency of recurrent AMI and revascularization was seen higher but lower inpatient mortality.